A new strategy to reduce the serious side effects of an important class of modern anticancer drugs (tyrosine kinase inhibitors) has been established jointly by an interdisciplinary team of researchers from the University of Vienna (Institute of Inorganic Chemistry) and the Medical University of Vienna (Institute for Cancer Research). The novel drug is supposed to restrict its activity with high selectivity to the malignant tumour.